Search Results for “cancer” – Page 166 – media

Novartis bags first-line approval for Zykadia

The European Commission has expanded the scope of Novartis’ Zykadia to include the first line treatment of patients with non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive.
- Source: pharmatimes
- 490
- June 30, 2017
cancer Company Insight New Approvals NSCLC Zykadia
Merck pauses Keytruda studies to assess patient deaths

Merck has paused new enrolment in two studies assessing its immunotherapy Keytruda treatment in combination with other therapies in multiple myeloma to address safety concerns.
- Source: pharmatimes
- 472
- June 13, 2017
asthma Clinical Trials keytruda
Second US approval for Merck, Pfizer’s Bavencio

Merck and Pfizer have announced a second accelerated approval in the US for Bavencio in less than two months, in this instance for certain patients with metastatic urothelial carcinoma.
- Source: pharmatimes
- 590
- May 10, 2017
cancer clinic Company Insight FDA gentic
Second US approval for Merck, Pfizer’s Bavencio

Merck and Pfizer have announced a second accelerated approval in the US for Bavencio in less than two months, in this instance for certain patients with metastatic urothelial carcinoma.
- Source: pharmatimes
- 573
- May 10, 2017
antibody Bavencio cancer New Approvals
NICE nods for Amgen’s rare leukaemia drug

Patients with a rare form of leukaemia look set to win routine access to a novel treatment option on the NHS in England and Wales after Amgen’s Blincyto was backed by cost watchdog NICE
- Source: pharmatimes
- 637
- May 3, 2017
cancer Company Insight NHS NICE therapy

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.